RhumbLine Advisers’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $703K | Sell |
51,293
-2,173
| -4% | -$29.8K | ﹤0.01% | 2441 |
|
|
2025
Q1 | $591K | Buy |
53,466
+2,196
| +4% | +$24.3K | ﹤0.01% | 2468 |
|
|
2024
Q4 | $546K | Buy |
51,270
+1,402
| +3% | +$14.9K | ﹤0.01% | 2627 |
|
|
2024
Q3 | $633K | Sell |
49,868
-609
| -1% | -$7.73K | ﹤0.01% | 2545 |
|
|
2024
Q2 | $847K | Buy |
50,477
+13,681
| +37% | +$230K | ﹤0.01% | 2329 |
|
|
2024
Q1 | $552K | Buy |
36,796
+2,090
| +6% | +$31.4K | ﹤0.01% | 2614 |
|
|
2023
Q4 | $521K | Buy |
34,706
+7,842
| +29% | +$118K | ﹤0.01% | 2636 |
|
|
2023
Q3 | $376K | Buy |
26,864
+6,458
| +32% | +$90.5K | ﹤0.01% | 2792 |
|
|
2023
Q2 | $211K | Buy |
+20,406
| New | +$211K | ﹤0.01% | 3215 |
|
|
2022
Q2 | – | Sell |
-23,152
| Closed | -$202K | – | 3240 |
|
|
2022
Q1 | $202K | Sell |
23,152
-912
| -4% | -$7.96K | ﹤0.01% | 2757 |
|
|
2021
Q4 | $229K | Sell |
24,064
-344
| -1% | -$3.27K | ﹤0.01% | 2797 |
|
|
2021
Q3 | $411K | Buy |
24,408
+505
| +2% | +$8.5K | ﹤0.01% | 2631 |
|
|
2021
Q2 | $365K | Sell |
23,903
-2,675
| -10% | -$40.8K | ﹤0.01% | 2711 |
|
|
2021
Q1 | $518K | Sell |
26,578
-2,070
| -7% | -$40.3K | ﹤0.01% | 2477 |
|
|
2020
Q4 | $516K | Buy |
28,648
+3,131
| +12% | +$56.4K | ﹤0.01% | 2434 |
|
|
2020
Q3 | $492K | Sell |
25,517
-3,570
| -12% | -$68.8K | ﹤0.01% | 2299 |
|
|
2020
Q2 | $760K | Buy |
29,087
+5,539
| +24% | +$145K | ﹤0.01% | 2167 |
|
|
2020
Q1 | $420K | Buy |
23,548
+143
| +0.6% | +$2.55K | ﹤0.01% | 2249 |
|
|
2019
Q4 | $781K | Buy |
23,405
+1,395
| +6% | +$46.6K | ﹤0.01% | 2191 |
|
|
2019
Q3 | $524K | Buy |
22,010
+931
| +4% | +$22.2K | ﹤0.01% | 2302 |
|
|
2019
Q2 | $758K | Buy |
+21,079
| New | +$758K | ﹤0.01% | 2181 |
|